INTERPRETING THYROID HORMONE LEVELS IN A PATIENT WITH GRAVES’ DISEASE ON ENOXAPARIN

Authors

  • Jean Mun Cheah
  • Pei Sun Tan
  • Mohd Idris Bin Mohammad Diah
  • Saieehwaran Menon
  • Xin Yi Ooi
  • Hui Chin Wong
  • Sy Liang Yong

DOI:

https://doi.org/10.15605/jafes.040.S1.116

Keywords:

Graves’ Disease, Enoxaparin, Thyroid Function Test Interference

Abstract

INTRODUCTION/BACKGROUND
Enoxaparin, a low molecular-weight heparin, can interfere with free T4 measurements by displacing thyroid hormones from their binding proteins, potentially giving rise to misleading results. Diagnosis becomes particularly challenging in Graves' disease when this interference occurs, as fluctuating thyroid function caused by shifting TSH receptor antibodies is rare in this condition.

CASE
We report a 38-year-old Malay female who was diagnosed with Grave’s disease in May 2024 and treated with carbimazole. Five months later, she was readmitted for dyspnea and hypoxia and diagnosed with a severe pulmonary embolism. Treatment included thrombolysis with alteplase, followed by anticoagulation therapy using enoxaparin.

Upon admission, her anti-thyroid therapy was withheld due to subclinical hypothyroidism, as evidenced by a slightly low free T4 (12.8 pmol/L) and elevated TSH (6.65 iU/L). During her prolonged hospital stay, reassessment revealed discordant thyroid hormone levels, with both free T4 and TSH being elevated, coinciding with the development of hypothyroid symptoms. Assay interference was ruled out through thyroid function tests performed in other laboratories. While anti-TSH receptor antibody was positive, anti-thyroid peroxidase antibody was normal. A multidisciplinary discussion between physicians and biochemical pathologists concluded that the discordant thyroid function test results were likely due to enoxaparin-induced interference (falsely elevated free T4) in the context of her underlying hypothyroid state (elevated TSH). Oral levothyroxine was initiated. Subsequently, her pulmonary embolism treatment was switched to oral rivaroxaban, and further thyroid function tests showed normal free T4 and TSH levels, corresponding to a clinically euthyroid state.

CONCLUSION
This case emphasizes that when managing Graves' disease with low molecular-weight heparin, clinicians should be aware of potential laboratory interference when interpreting discordant thyroid function test results.

Downloads

Download data is not yet available.

Author Biographies

Jean Mun Cheah

Endocrine Unit, Hospital Tengku Ampuan Rahimah, Selangor, Malaysia

 

Pei Sun Tan

Endocrine Unit, Hospital Tengku Ampuan Rahimah, Selangor, Malaysia

 

Mohd Idris Bin Mohammad Diah

Endocrine Unit, Hospital Tengku Ampuan Rahimah, Selangor, Malaysia

 

Saieehwaran Menon

Endocrine Unit, Hospital Tengku Ampuan Rahimah, Selangor, Malaysia

 

Xin Yi Ooi

Endocrine Unit, Hospital Tengku Ampuan Rahimah, Selangor, Malaysia

 

Hui Chin Wong

Endocrine Unit, Hospital Tengku Ampuan Rahimah, Selangor, Malaysia

 

Sy Liang Yong

Endocrine Unit, Hospital Tengku Ampuan Rahimah, Selangor, Malaysia

 

References

*

Downloads

Published

2025-05-30

How to Cite

Cheah, J. M., Tan, P. S., Diah, M. I. B. M., Menon, S., Ooi, X. Y., Wong, H. C., & Yong, S. L. (2025). INTERPRETING THYROID HORMONE LEVELS IN A PATIENT WITH GRAVES’ DISEASE ON ENOXAPARIN. Journal of the ASEAN Federation of Endocrine Societies, 40(S1), 69. https://doi.org/10.15605/jafes.040.S1.116